|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Asthma Phenotypes A Changing Paradigm
Datamonitor, March 2007, Pages: 178
An estimated 34 million people are diagnosed with asthma in the major markets. The disease can be broken down into various phenotypes, differentiated by severity, trigger, or predominant inflammatory type. These phenotypes may have important consequences for future approaches to treat asthma in a more targeted fashion, doing away with the one-size-fits-all approach.
Scope of this title:
Analysis of the main asthma phenotypes and their pathobiological characteristics. Overview of the prevalence of the main phenotypes in asthma. Assessment of key unmet needs and the opportunities they offer for new product development Analysis of the future role of phenotypes and their impact in drug development
Highlights of this title:
Refractory asthma seems to be resistant to corticosteroids, and some refractory patients also suffer from chronic airflow obstruction. Resistant disease is thought to afflict about 10% of asthma patients, whose unmet medical needs are for obvious reasons very high. On average, 60% of the adult asthmatic population suffer from allergic asthma. These patients are often well controlled with an early onset of disease and less severe symptoms compared to the non-allergic phenotype. Immunotherapy is suggested to be beneficial for some of the more severe allergic asthmatics. Two inflammatory phenotypes dominate in asthma: eosinophilic and neutrophilic. These types of inflammation can be seen across a variety of phenotypes, although it is thought that eosinophilic inflammation is mostly associated with allergic asthma and neutrophilic inflammation is associated with refractory asthma and chronic airflow obstruction.
Reasons to order your copy:
Evaluate different asthma phenotypes and their prevalence in the seven major markets Explore differential treatment and the unmet needs of the most important asthma phenotypes Appreciate the impact of various phenotypes on the future of drug development for asthma
Customers who bought this item also bought
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Asthma Evaluation and Management 2007 Update
Stakeholder Perspectives: Asthma - Improvements to Combination Inhalers Will Satisfy a Growing Patient Base
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Stakeholder Opinions: Community Acquired Respiratory Tract Infections - Room for Ketek?
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Stakeholder Opinions: Minimally Invasive Spinal Surgery - Surgeons Await Helping Hand from Manufacturers
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A Market Yet to Reach its Full Potential
|
|
|
|
